Analyst Coverage
Overview
CLINUVEL does not provide financial guidance on its earnings and financial performance. CLINUVEL does not endorse, confirm, or express a view as to the accuracy of the following analyst reports and the forecasts contained within them and does not make any representation that its earnings will fall within the range of the analyst’s forecasts. CLINUVEL does not induce, incentivise, or remunerate analysts and journalists to publish and recommend CLINUVEL in their reports or mainstream media channels.
Firm/Institution |
Analyst |
Date of Publication |
Analyst Profile |
Firm/Institution Profile |
|---|---|---|---|---|
| Bioshares | Mark Pachacz | Latest Report: No. 964, 28 October 2024 Initiation Date: No. 195, 01 December 2006 | Mark Pachacz is co-founder (with David Blake [1962-2021]) and editor of Bioshares. He is a chemical engineer by training and a graduate of Monash University and the Securities Institute of Australia. | Bioshares is published by Blake Industry and Market Analysis Pty Ltd. Since 2000, Bioshares has cemented a reputation for highly knowledgeable insightful, and independent coverage of life sciences, pharmaceutical and healthcare companies. |
| MA Moelis Australia | Sarah Mann | Latest Report: 28 October 2023 Initiation Date: 17 April 2019 | Sarah Mann is a prominent analyst focused on the healthcare sector. With Moelis Australia since mid-2016, Sarah was previously an analyst at Credit Suisse. She holds a Bachelor of Liberal Studies from the University of Sydney with an undergraduate thesis in Immunology. At MA Moelis Australia, Sarah covers companies across the healthcare and consumer sectors listed on the Australian Securities Exchange (ASX). | MA Moelis Australia is the corporate advisory and equities division of the MA Financial Group (ASX:MAF). They provide strategic and financial advice for mergers and acquisitions, equity capital markets, debt capital markets and restructuring, as well as specialist securities research, sales, and trading execution services. Since their launch in 2009 they have advised on over A$100bn worth of transactions. Global investment bank, Moelis & Company (NYSE:MC), is a substantial shareholder in MA Financial Group. |
| Jefferies Australia | David Stanton & Vanessa Thomson | Latest Report: 29 August 2024 Initiation Date: 13 October 2020 | Dr Stanton is Head of Healthcare Equity Research Australia at Jefferies Australia. He is a qualified Medical Specialist, holds an MBA, and is an experienced and well-regarded healthcare analyst. Dr Stanton has followed CLINUVEL’s development program since 2007. With Jefferies since September 2019, he has held senior analytical roles over 15 years with CSLA, Nomura, and ABN Amro.
An Analyst at Jefferies Australia since September 2019, Ms Thomson previously held analyst and research positions at CLSA, Altius Asset Management, ING Investment Management. She holds bachelor’s degrees in science, majoring in mathematics, and an MBA. |
Jefferies Australia is a subsidiary of Jefferies Financial Group Inc (NYSE:JEF), a leading global, full-service investment banking and capital markets firm. They offer a range of investment banking, equities, fixed income, asset and wealth management products and services through subsidiaries worldwide. Healthcare is one of the firm’s 12 focus areas, maintaining a dedicated global healthcare research team which issues analyst coverage on over 270 companies in the sector. The annual Jefferies Global Healthcare Conference is recognised as the largest life sciences investment event in Europe. |
| Wilsons Advisory | Shane Storey | Latest Report: 21 November 2024 Initiation Date: 26 April 2021 | Dr Storey has covered the healthcare sector at Wilsons for more than a decade and previously held positions in drug development, R&D project management, and venture capital. | With a history spanning over 125 years, Australian-based firm Wilsons offers services in private wealth management, corporate finance, research and investment strategy, and institutional sales. Wilsons is focused on investment opportunities in emerging and mid-cap markets, and undertakes in-depth research on the healthcare, technology, financial services, consumer, food, and agriculture sectors, covering over 90 listed companies in Australia. |
| Bell Potter Securities | Thomas Wakim & John Hester | Latest Report: 29 August 2024 Initiation Date: 04 October 2023 | Thomas Wakim has been with Bell Potter since May 2023 and focuses on biotech and healthcare companies. He previously held roles in a clinical stage biopharmaceutical in business development and commercial analysis. He holds a Bachelor of Science and Bachelor of Commerce from the University of New South Wales.
John Hester is a prominent senior sell-side analyst specialising in small- and mid-cap healthcare stocks. With Bell Potter since September 2013, he previously held a range of analyst roles. He holds a Bachelor of Economics, Accounting and Finance from Macquarie University and a post graduate diploma from Finsia. |
Bell Potter is a leading Australian stockbroking, investment and financial advisory firm that provides a comprehensive offering of financial services to individuals, institutions, and corporations. Established in 1970, they have a team of 325 advisors, A$37.5 billion funds under advice and is part of the Bell Financial Group (ASX:BFG). |
| Morgans Financial | Iain Wilkie, Derek Jellinek & Emily Porter | Latest Report: 29 August 2024 Initiation Date: 15 November 2023 | Iain Wilkie joined the Morgans Research Team in 2014 as an analyst with a focus on healthcare. Since then, he has developed broad knowledge across the medical device and biotechnology sub-indices. He holds a Bachelor of Business Management and Diploma of Financial Planning.
Dr Jellinek joined Morgans in 2015 with extensive experience in healthcare analysis. He holds a Bachelor of Science, PhD in Medicine, and an MBA. Ms Porter joined the Morgans in 2019 and the Research Team in May 2021 with focus on the Healthcare sector. She holds a Bachelor of Psychological Science (Honours). |
Morgans Financial is Australia’s largest national full-service stockbroking and wealth management network and covers over 200 listed stocks. They have been providing investment and stockbroking services since 1982. |
| Morningstar | Shane Ponraj | Latest Report: 18 November 2024 Initiation Date: 15 November 2023 | Since 2019, Shane Ponraj has been an equity analyst specialising in the healthcare sector for Morningstar Australasia, a wholly owned subsidiary of Morningstar Inc. He holds bachelor’s degrees in engineering and commerce and is a Chartered Financial Analyst. | Morningstar (Nasdaq:MORN) is a leading global provider of independent investment research. |
Each research report is issued by a holder of an Australian Financial Services Licence. CLINUVEL does not distribute the original or copies of the analyst reports in observance of copyrights.